Adaptimmune Therapeutics Plc EBIT margin
Was ist das EBIT margin von Adaptimmune Therapeutics Plc?
EBIT margin von Adaptimmune Therapeutics Plc ist -50.11%
Was ist die Definition von EBIT margin?
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
EBIT margin von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Adaptimmune Therapeutics Plc
Was macht Adaptimmune Therapeutics Plc?
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Unternehmen mit ebit margin ähnlich Adaptimmune Therapeutics Plc
- Hindustan Copper hat EBIT margin von -50.81%
- 16394 hat EBIT margin von -50.69%
- Arrow Greentech hat EBIT margin von -50.66%
- Blueprint Medicines Corp hat EBIT margin von -50.50%
- Carnival & Plc hat EBIT margin von -50.40%
- Carnival plc hat EBIT margin von -50.40%
- Adaptimmune Therapeutics Plc hat EBIT margin von -50.11%
- Standard BioTools Inc hat EBIT margin von -50.06%
- Polar Power Inc hat EBIT margin von -49.73%
- Arcturus Therapeutics Inc hat EBIT margin von -49.71%
- Datasea Inc hat EBIT margin von -49.63%
- Envista Corp hat EBIT margin von -49.58%
- Seeing Machines hat EBIT margin von -49.41%